HCG for Research: Human Chorionic Gonadotropin Explained
HCG (Human Chorionic Gonadotropin) for research purposes: mechanism of action as LH receptor agonist, regulatory status, quality criteria and research applications.
Human chorionic gonadotropin (HCG) is a glycoprotein hormone that has played a role in clinical medicine and basic research for decades. It is naturally produced by the placenta during pregnancy and is primarily known as the pregnancy hormone. For research, however, HCG is interesting for a different reason: it binds to the LH/CG receptor and thereby mimics the action of luteinizing hormone (LH). Researchers looking to obtain HCG should understand the mechanism of action, regulatory status and quality criteria.
Prescription Drug
HCG is classified as a prescription drug in the EU and the USA. Approved preparations such as Pregnyl and Ovitrelle may only be used under medical supervision. HCG from PeptidesDirect is intended exclusively as a research reagent and not for human consumption or therapeutic use.
Reproductive hormone that mimics luteinizing hormone (LH) activity. Used in research on testosterone production, fertility, and hormonal regulation. Available in 6,000 IU and 15,000 IU vials.
Structure and Biochemistry
HCG is a heterodimeric glycoprotein with a molecular mass of approximately 36.7 kDa. It consists of two non-covalently linked subunits:
-
Alpha subunit (14.5 kDa): 92 amino acids. This subunit is identical to the alpha subunit of other pituitary glycoprotein hormones, including LH, FSH and TSH. It contains two N-linked glycosylation sites at positions 52 and 78.
-
Beta subunit (22.2 kDa): 145 amino acids. This subunit confers biological specificity to HCG. It has two N-linked and four O-linked glycosylation sites. The key structural difference from LH lies in a carboxy-terminal extension of 30 amino acids (C-Terminal Peptide, CTP) carrying four O-linked oligosaccharides.
Why HCG Has a Longer Duration Than LH
The CTP extension of the beta subunit is directly responsible for the significantly longer half-life of HCG compared to LH. While LH has a half-life of approximately 20 minutes, the terminal half-life of HCG is 24-36 hours. This difference makes HCG useful for research designs requiring prolonged receptor stimulation.
Mechanism of Action: LH Receptor Agonism
HCG and LH bind to the same receptor, the LH/CG receptor (LHCGR), a G protein-coupled receptor of the rhodopsin family. Signal transduction proceeds through several pathways:
Primary pathway: Receptor binding activates adenylyl cyclase via Gs proteins, leading to cAMP production. cAMP activates protein kinase A (PKA), which initiates cholesterol release from lipid droplets and transport into the mitochondria. There, cholesterol is transported by the StAR protein (Steroidogenic Acute Regulatory Protein) into the inner mitochondrial membrane, where steroidogenesis begins.
Secondary pathways: In addition to the cAMP/PKA pathway, the LHCGR also activates ERK1/2 phosphorylation and PI3K/AKT signalling pathways. Research data from 2016 show that HCG is approximately 10-fold more potent than LH in cAMP recruitment and slightly more potent in cAMP-dependent ERK1/2 phosphorylation (Riccetti et al., Reproductive Biology and Endocrinology, 2017).
In Leydig cells of the testis, this signalling cascade leads to testosterone synthesis. The enzymatic chain runs from cholesterol through pregnenolone to testosterone, catalysed by enzymes of the smooth endoplasmic reticulum.
Clinically Approved Indications
HCG is approved as a prescription drug in the EU and the USA. Clinical applications are narrowly defined:
Fertility in Women
Ovitrelle (choriogonadotropin alfa, recombinant) has held EU-wide approval since 2001 for triggering final follicular maturation and luteinisation following stimulation of follicular growth in assisted reproduction. Use is exclusively under the supervision of reproductive medicine specialists.
Hypogonadotropic Hypogonadism in Men
In confirmed hypogonadotropic hypogonadism (secondary to pituitary insufficiency), HCG can stimulate endogenous testosterone production. This application uses the described mechanism of Leydig cell stimulation.
Cryptorchidism
HCG is used in prepubertal boys with cryptorchidism when no anatomical obstruction is present. The clinical response rate is limited: studies report complete descent in approximately 25% of cases and partial descent in a further 32%.
Regulatory Status
EU
In the EU, HCG is classified as a prescription-only medicine. Ovitrelle (recombinant HCG) holds a centralised EMA authorisation. Urinary-derived preparations such as Pregnyl are available through national authorisations. Use is restricted to approved indications under medical supervision.
USA
In the USA, HCG has a particular regulatory history. With the implementation of the Biologics Price Competition and Innovation Act (BPCIA) in March 2020, HCG was reclassified as a biological product. Compounding of HCG by pharmacies is no longer permissible, as biological products under Section 351 of the Public Health Service Act must be licensed and do not qualify for the compounding exemptions under Sections 503A and 503B of the FD&C Act. This transition has restricted HCG availability in the USA and increased costs.
Research Context
The regulatory status as a prescription drug underscores that HCG is not a harmless supplement. It is an active hormonal agent with a defined activity profile and side effect potential. Research reagents are not intended for human use.
Research Applications
Beyond clinical indications, HCG is used in various research contexts:
Reproductive Endocrinology
HCG serves as a tool for studying LH/CG receptor signal transduction, Leydig cell function and steroidogenesis. In cell culture models, HCG is routinely used to stimulate Leydig cells for investigating testosterone synthesis pathways.
Superovulation in Animal Models
In combination with PMSG (Pregnant Mare Serum Gonadotropin), HCG is used as standard in superovulation protocols required for generating genetically modified animal models. These include CRISPR-Cas9-based gene modifications, pronuclear injection and ES cell-based gene targeting.
Neuroprotection Research
Preclinical studies have provided evidence that HCG may exhibit neuroprotective effects in animal models of neurodegenerative diseases. In MPTP-induced Parkinson's models, a reduction in dopaminergic cell loss was observed, possibly mediated through inhibition of GSK3-beta activation via the LHCGR pathway. These data are preclinical and require further validation.
Immunological Research
Initial investigations suggest possible immunomodulatory potential of HCG, for example in the context of transplantation research. The evidence base here is still thin.
Safety Profile and Side Effects
The side effect profile of HCG is well documented from clinical use. The following information comes from the specialist literature and relates to clinical application.
Common side effects:
- Injection site pain
- Headache
- Irritability and mood changes
- Fatigue
- Oedema
Serious adverse reactions:
- Ovarian hyperstimulation syndrome (OHSS) in women, potentially life-threatening
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Anaphylactic reactions (rare)
- Gynaecomastia in men
- Precocious puberty in children treated for cryptorchidism
A study by Hsieh et al. (2022, PMC) examined the safety of HCG monotherapy in 175 men and reported no significant adverse effects. However, the safety profile depends heavily on dosage, duration of use and individual factors.
Quality Criteria
As a glycoprotein, HCG is structurally more complex than many shorter research peptides. Quality assessment therefore requires particular attention.
What to Look For
Independent analysis: Every HCG batch at PeptidesDirect is tested by Janoshik Analytical. External laboratory reports help verify identity and purity.
Purity profile: HPLC purity analysis and mass spectrometry for identity confirmation are minimum requirements for a meaningful Certificate of Analysis.
Glycosylation pattern: The biological activity and half-life of HCG are highly dependent on the glycosylation state. Recombinant HCG (e.g. from CHO cells) and urinary-derived HCG may differ in this respect.
EU shipping: PeptidesDirect ships from within the EU with full tracking. Delivery in 2-3 working days within Europe, no customs fees for EU recipients.
Storage and Handling
Lyophilised HCG (powder):
- Store at -20 degrees C or colder
- Stable for months in this form
- Protect from moisture and direct light
Reconstituted HCG (in solution):
- Store in the refrigerator at 2-8 degrees C
- Use within 30 days
- Do not freeze; freeze-thaw cycles damage the protein structure
- Use bacteriostatic water as solvent
USP-grade sterile water with 0.9% benzyl alcohol - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
Related Products
HCG acts in the context of the hypothalamic-pituitary-gonadal axis. Other products used in related research areas:
Recombinant human growth hormone (191 amino acids), identical to the body's own GH. Regulates IGF-1 production, metabolism, body composition, and cellular repair. Available in 10 IU, 15 IU, and 100 IU vials.
Tanning peptide that activates melanin production in the skin. Stimulates melanocyte receptors for natural UV-free pigmentation. Also researched for appetite regulation and libido effects.
Frequently Asked Questions
Order HCG for Research
Human chorionic gonadotropin as a research reagent, with external batch testing by Janoshik Analytical and EU shipping.
Reproductive hormone that mimics luteinizing hormone (LH) activity. Used in research on testosterone production, fertility, and hormonal regulation. Available in 6,000 IU and 15,000 IU vials.